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OBJECTIVES We sought to determine the prognostic significance of the metabolic syndrome in hypertension.
BACKGROUND Increased cardiovascular risk in hypertensive patients might be partially attributable to
metabolic disturbances.
METHODS We prospectively followed for up to 10.5 years (mean 4.1 years) a total of 1,742 hypertensive
patients without cardiovascular disease (55% men; blood pressure [BP] 154/95 mm Hg; age
50 12 years). A modified National Cholesterol Education Program definition for metabolic
syndrome was used, with body mass index in place of waist circumference.
RESULTS During follow-up, 162 patients developed cardiovascular events (2.28 events/100 patient-
years). Event rates in the groups with one to five characteristics of the metabolic syndrome
were 1.54, 1.96, 2.97, 3.35, and 5.27 per 100 patient-years, respectively (p  0.001). A total
of 593 patients (34%) had the metabolic syndrome. Patients with the syndrome had an almost
double cardiovascular event rate than those without (3.23 vs. 1.76 per 100 patient-years, p 
0.001). After adjustment for age, gender, total cholesterol, creatinine, smoking, left
ventricular hypertrophy, and 24-h systolic BP, the risk of developing cardiovascular events
was still higher in patients with the metabolic syndrome (hazard ratio [HR] 1.73, 95%
confidence interval [CI] 1.25 to 2.38). The syndrome was an independent predictor of both
cardiac and cerebrovascular events (HRs 1.48 and 2.11, respectively). The adverse prognostic
value of the metabolic syndrome was attenuated but still significant among the 1,637 patients
without diabetes (HR 1.43, 95% CI 1.02 to 2.08).
CONCLUSIONS In hypertensive subjects, the metabolic syndrome amplifies cardiovascular risk associated with
high BP, independent of the effect of several traditional cardiovascular risk factors. (J Am
Coll Cardiol 2004;43:1817–22) © 2004 by the American College of Cardiology Foundations
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the metabolic syndrome represents a cluster of cardiovas-
ular risk factors closely linked to insulin resistance (1),
hose prevalence is high and rapidly rising in the Western
opulation (2,3). The working definition of the metabolic
yndrome proposed in the Third Report of the National
holesterol Education Program Expert Panel on Detection,
valuation, and Treatment of High Blood Cholesterol in
dults (ATP-III) (4) is based on the presence of three or
ore of the following characteristics: abdominal obesity,
igh blood pressure (BP), high fasting glucose, high tri-
lycerides, and reduced levels of high-density lipoprotein
holesterol. Recently, a modification of the ATP-III defi-
ition has been developed (5,6), in which waist circumfer-
nce as a measure of adiposity was replaced by body mass
ndex (BMI), which has been shown to predict metabolic
isturbances as strongly as waist circumference (7–9). Ac-
ording to the latter definition, the metabolic syndrome is a
redictor of future coronary heart disease in hypercholester-
lemic men (5) and of cardiovascular morbidity in women
ithout a history of cardiovascular disease (6).
High BP is considered one of the key features of the
From the *Unit of Internal Medicine, Angiology and Arteriosclerosis, University of
erugia; and †Department of Cardiology, Perugia General Hospital, Perugia, Italy.
Manuscript received November 13, 2003; revised manuscript received Decemberc1, 2003, accepted December 16, 2003.yndrome (4,10), and the recent European Society of
ypertension/European Society of Cardiology clinical
uidelines for the management of hypertension underscore
he importance of identifying hypertensive patients with the
etabolic syndrome as a group at high risk for the devel-
pment of cardiovascular disease (11). Although the prob-
em is now thought to be of paramount importance, no
ystematic study has been performed to determine the
rognostic importance of the metabolic syndrome in the
ypertensive population. In the setting of the Progetto
pertensione Umbria Monitoraggio Ambulatoriale (PIUMA)
tudy, we had the opportunity to investigate the relationship
etween the metabolic syndrome and incident cardiovascu-
ar disease in subjects with essential hypertension without
revalent cardiovascular disease, who underwent a thorough
linical work-up at the baseline examination and were then
rospectively followed for up to 10 years.
ETHODS
he PIUMA study is a prospective follow-up study of
aucasian adult subjects with essential hypertension
12,13), carried out in Umbria, Italy. A total of 1,750 white
ubjects enrolled between 1988 and 1996 were included in
he present analysis. All study subjects fulfilled the following
riteria: 1) office systolic BP 140 mm Hg, diastolic BP

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ntervals; 2) no previous treatment for hypertension (70%)
r withdrawal from antihypertensive drugs at least four weeks
efore the study; 3) no clinical or laboratory evidence of heart
ailure, coronary heart disease, previous stroke, valvular defects,
econdary causes of hypertension, or important concomitant
isease; and 4) one or more valid BP measurement per hour
ver 24 h. At the baseline evaluation, hypertensive patients
ere classified by the presence or absence of the metabolic
yndrome on the basis of the modified ATP-III criteria (4–6).
y selection, all patients were hypertensive and hence fulfilled
t least one of the ATP-III criteria.
The remaining cut-off values were: 1) serum triglyceride
evels 1.69 mmol/l (150 mg/dl); 2) serum high-density
ipoprotein cholesterol 1.04 mmol/l (40 mg/dl) in men
nd 1.30 mmol/l (50 mg/dl) in women; 3) fasting plasma
lucose 6.11 mmol/l (110 mg/dl); and 4) BMI 29.3
g/m2 in men and 27.0 kg/m2 in women. Hypertensive
atients were classified as having the metabolic syndrome if
hey fulfilled two or more of the aforementioned criteria, in
ddition to hypertension. The BMI cut-off values were
quivalent in a regression analysis to a waist circumference
f 102 cm in men and 88 cm in women in a subgroup of 254
ypertensive patients from the PIUMA data base, in whom
MI showed a strong direct association with waist circum-
erence (r  0.78, p  0.001). Compared with the original
TP-III definition, the modified definition resulted in
isclassification of only 5.1% of the patients (13 of 254
atients). Diabetes mellitus was diagnosed by a fasting
lucose level 7.0 mmol/l (126 mg/dl) or a clinical diag-
osis of diabetes with dietary, oral, or insulin treatment. All
ubjects gave oral or written informed consent to participate
n the study, which was approved by the institutional review
oard.
aseline measurements. Office BP was measured by a
hysician in the hospital clinic, using a mercury sphygmo-
anometer, after the subject sat for 10 min. The average
f six or more measurements for two or more sessions was
onsidered for the analysis. Ambulatory BP was recorded
ith an oscillometric device (models 90202 and 90207;
paceLabs, Redmond, Washington), which was set to take
reading every 15 min throughout 24 h (14). The BMI was
alculated as weight in kilograms divided by the square of
Abbreviations and Acronyms
ATP-III  Adult Treatment Panel III of the National
Cholesterol Education Program
BMI  body mass index
BP  blood pressure
CI  confidence interval
HR  hazard ratio
LV  left ventricular
PIUMA  Progetto Ipertensione Umbria Monitoraggio
Ambulatorialeeight in meters. Electrocardiographic (ECG) left ventric- slar (LV) hypertrophy was defined according to the Perugia
riterion (S-wave in lead V3  R-wave in lead aVL  2.4
V in men and 2.0 mV in women, or typical LV strain,
r a Romhilt-Estes score of 5 points) (15), which shows a
reater attributable risk for cardiovascular morbidity and
ortality than do other criteria (16).
ollow-up procedures and end-point evaluation. All
ubjects were followed by their family physicians, in coop-
ration with the outpatient clinic of the referring hospital.
t the follow-up visit, 70% of the study patients were taking
ntihypertensive drugs, and 30% were receiving lifestyle
easures only. Aspirin and hypolipidemic drugs were being
sed in 3% and 9% of the population, respectively. Contacts
ith family physicians and telephone interviews were peri-
dically undertaken to determine the occurrence of cardio-
ascular disease. For the subjects who developed a cardio-
ascular event, hospital record forms and other available
riginal source documents were reviewed in conference by
he authors. Cardiovascular events included new-onset cor-
nary artery disease (myocardial infarction, unstable angina
ith documentation of ischemic ECG changes, sudden
ardiac death, or coronary revascularization procedure),
ongestive heart failure that required hospitalization, stroke,
ransient cerebral ischemia, and symptomatic aorto-iliac
cclusive disease verified by angiography (12).
tatistical analysis. Survival curves were compared with
he use of the Mantel (log-rank) test. For those subjects who
xperienced multiple events, survival analysis was restricted
o the first event. The effect of prognostic factors on survival
as evaluated with the use of the stepwise Cox semipara-
etric regression model. The assumption of proportionality
or the Cox model was tested through visual inspection, and
o violation of proportional hazards was found. We tested
he variables of age (years), gender, office and 24-h systolic
P (mm Hg), serum total cholesterol (mmol/l), smoking
abits (previous, never, or current smokers), family history
f premature cardiovascular disease (yes, no), and antihy-
ertensive treatment at the time of follow-up contact
lifestyle measures only, diuretics and/or beta-blockers,
ngiotensin-converting enzyme inhibitors and/or Ca2-
hannel blockers, other drugs or other antihypertensive drug
ombinations). Although at the follow-up visit only a small
umber of hypertensive patients were taking either aspirin
r hypolipidemic drugs, the effects of those therapies were
lso evaluated in the regression model. The SPSS statistical
ackage, release 9.0 (SPSS Inc., Chicago, Illinois), was used
o perform the analyses.
ESULTS
ollow-up data were available for 1,742 (99.5%) of the
,750 hypertensive patients, and only 0.5% were lost to
ollow-up. A total of 593 patients (34.0%) had the meta-
olic syndrome. Subjects with the metabolic syndrome were
lder and had a longer duration of hypertension and higher
ystolic BP (Table 1). The two groups did not differ in terms
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May 19, 2004:1817–22 Prognosis of the Metabolic Syndromef gender distribution, smoking habits, total and low-
ensity lipoprotein cholesterol concentrations, and LV hy-
ertrophy.
urvival analysis. During follow-up of 4.1  2 years
range 1.0 to 10.5 years), 162 patients had a new cardiovas-
ular morbid event (2.28 events/100 patient-years). Specif-
cally, there were 39 subjects with myocardial infarction, 7
ith sudden cardiac death, 1 with cardiac death from other
auses, 20 with unstable angina, 9 with coronary revascu-
arization procedures, 14 with heart failure that required
ospitalization, 43 with stroke, 16 with transient cerebral
schemia, and 13 with new-onset aorto-iliac occlusive dis-
ase that required revascularization. As shown in Figure 1,
he event rate increased progressively with an increasing
umber of components of the metabolic syndrome (1.54,
.96, 2.97, 3.35, and 5.27, respectively, per 100 patient-
ears in the groups with 1 to 5 characteristics; p  0.001).
verall, there were 80 first cardiovascular events in the
roup with the metabolic syndrome (3.23 events per 100
atient-years) and 82 events in the group without (1.76
vents per 100 patient-years). Event-free survival curves
Table 1. Clinical Characteristics of Study Subj
Data
Metabolic
Abs
(n  1
Age (yrs) 49.8 
Men (%) 55
Body mass index (kg/m2) 25.6 
Current smokers (%) 24
Diabetes (%) 2
Duration of hypertension (yrs) 3.4 
Office systolic BP (mm Hg) 153 
Office diastolic BP (mm Hg) 96 
24-h systolic BP (mm Hg) 135 
24-h diastolic BP (mm Hg) 86 
Total cholesterol (mmol/l) 5.51 
HDL cholesterol (mmol/l) 1.35 
LDL cholesterol (mmol/l) 3.56 
Triglycerides (mmol/l) 1.17 (0.8
Left ventricular hypertrophy (%) 16
Data are presented as the mean value  SD, percentage, or
BP  blood pressure; HDL  high-density lipoprotein;
igure 1. Cardiovascular (CV) event rate among 1,742 hypertensive
atients grouped by number of characteristics of the metabolic syndrome.
ee text for details. wiffered significantly among the two groups (log-rank value
45.4, p  0.001) (Fig. 2).
In a multivariate analysis, the metabolic syndrome main-
ained an association with subsequent cardiovascular events
fter adjustment for several potential confounders (Table 2).
atients with the metabolic factors had a 73% greater age-
nd risk factor-adjusted excess cardiovascular risk (hazard
atio [HR] 1.73, 95% confidence interval [CI] 1.25 to 2.38;
 0.001). The metabolic syndrome was also an indepen-
ent risk factor for “hard” cardiovascular events (i.e., after
he exclusion of angina, coronary revascularizations, and
ongestive heart failure [HR 1.62, 95% CI 1.13 to 2.32; p
.01]). The prevalences of the single components of the
etabolic syndrome are shown in Table 3, along with their
isk factor–adjusted HR.
en versus women. Event-free survival analysis was per-
ormed separately in men and women. In a multivariate Cox
y Metabolic Pattern
ome Metabolic Syndrome
Present
(n  593) p Value
51.4  11 0.009
55 0.86
29.1  4 0.001
27 0.12
14 0.001
4.8  7 0.001
157  21 0.001
97  11 0.27
138  17 0.001
86  11 0.70
5.60  1.1 0.08
1.07  0.3 0.001
3.55  1.0 0.78
4) 1.96 (1.51–2.59) 0.001
18 0.22
n value (interquartile range).
 low-density lipoprotein.
igure 2. Cardiovascular event-free survival curves in hypertensive patientsects b
Syndr
ent
,149)
12
3
5
19
10
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1.1
0.3
0.9
7–1.5
mediaith (thick line) or without (thin line) the metabolic syndrome.
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Prognosis of the Metabolic Syndrome May 19, 2004:1817–22egression model, the metabolic syndrome independently
redicted cardiovascular events in men (HR 1.63, 95% CI
.11 to 2.39; p 0.02), as well as in women (HR 1.80, 95%
I 1.02 to 3.15; p  0.048).
ardiac versus cerebrovascular events. We also evaluated
he prognostic impact of the metabolic syndrome on cardiac
nd cerebrovascular events taken separately. Compared with
atients without the metabolic syndrome, patients with it
ad a higher rate of both cardiac events (1.77 vs. 1.07
vents/100 patient-years; log-rank  4.95, p  0.026) and
erebrovascular events (1.41 vs. 0.59 events/100 patient-
ears; log-rank  14.96, p  0.001). Both differences
emained significant in a multivariate Cox model (HR 1.48,
5% CI 1.01 to 2.27, p  0.04 for cardiac events; HR 2.11,
5% CI 1.27 to 3.50, p  0.001 for cerebrovascular events).
nfluence of diabetes. To further explore whether the
elationship between the metabolic syndrome and prognosis
as independent of the presence of diabetes mellitus, we
epeated the survival analysis after exclusion of patients with
iabetes mellitus (n  105). In the 1,637 hypertensive
atients without diabetes, the relationship between the
etabolic syndrome and cardiovascular morbidity was at-
enuated, but the event rate was still significantly higher in
he presence of the metabolic syndrome (2.42 vs. 1.66 events
er 100 patient-years, log-rank  5.91, p  0.02). In this
roup (Table 4), patients with the metabolic syndrome had
significantly higher age- and risk factor–adjusted rate of
able 2. Predictors of Cardiovascular Morbidity in a
ultivariate Cox Model in 1,742 Hypertensive Patients
Variable
Adjusted HR*
(95% CI) p Value
etabolic syndrome (yes vs. no) 1.73 (1.25–2.38) 0.001
ge (12 yrs) 2.17 (1.81–2.59) 0.001
ender (male vs. female) 1.61 (1.11–2.33) 0.01
igarette smoking (yes vs. no) 1.60 (1.12–2.28) 0.009
4-h systolic BP (15 mm Hg) 1.40 (1.21–1.61) 0.001
erum cholesterol (1 mmol/l) 1.20 (1.01–1.43) 0.04
erum creatinine (18 mol/l) 1.15 (1.06–1.24) 0.002
eft ventricular hypertrophy (yes vs. no) 1.88 (1.29–2.73) 0.001
For continuous variables, the adjusted hazard ratio associated with each standard
eviation increase is reported. A family history of premature cardiovascular disease,
ffice blood pressure, heart rate, and treatment status (antihypertensive, hypolipidemic
nd aspirin) failed to enter the final equation.
BP  blood pressure; CI  confidence interval; HR  hazard ratio.
Table 3. Prevalence and Prognostic Significanc
Syndrome in 1,742 Hypertensive Patients
Variable
High serum triglycerides (1.69 mmol/l)
Low HDL cholesterol (1.04 mmol/l in men,
1.30 mmol/l in women)
High fasting plasma glucose (6.11 mmol/l)
Obesity (body mass index 29.3 kg/m2 in men,
27.0 kg/m2 in women)
*Adjusted for age, gender, smoking, 24-h systolic blood pres
left ventricular hypertrophy.Abbreviations as in Tables 1 and 2.ardiovascular events than did patients without it (HR 1.43,
5% CI 1.02 to 2.08; p  0.03).
ISCUSSION
he new finding of this prospective study is that the
etabolic syndrome is an independent predictor of subse-
uent cardiovascular disease in initially untreated men and
omen with essential hypertension who had no clinically
vert cardiovascular disease at the baseline examination.
he adverse prognostic effect of the metabolic syndrome
as independent of traditional cardiovascular risk factors,
ncluding LV hypertrophy (15,16) and 24-h BP, which is a
etter risk marker than office BP (12). Most notably, the
ssociation between the metabolic syndrome and future
ardiovascular morbidity also held in patients without dia-
etes mellitus at the baseline examination. Hence, this study
rovides evidence that the metabolic syndrome may be
seful as an integrating index of the overall burden imposed
y metabolic factors on the cardiovascular system in hyper-
ensive patients.
Several studies have shown that insulin resistance/
yperinsulinemia, a hallmark of the metabolic syndrome (1),
s a predictor of ischemic heart disease in the population at
arge (17–21) and in patients with type II diabetes (22). In
eople with a family history of type II diabetes, individuals
ho had the metabolic syndrome, according to the World
ealth Organization (WHO) (23), had a higher mortality
24). However, patients with the metabolic syndrome had a
igher prevalence of cardiovascular disease and diabetes at
aseline, and no adjustment for those confounding factors
as allowed in that study. In middle-aged Finnish men, the
etabolic syndrome, based on definitions by the ATP-III
nd WHO, predicted an increased all-cause and cardiovas-
ular mortality (3). Using a modified ATP-III definition
ith BMI in place of waist circumference, the metabolic
yndrome was found to predict coronary heart disease in
ypercholesterolemic men (5) and in apparently healthy
omen (6). Still, in the latter study, plasma glucose levels
ere not collected, and no adjustment was made for
mportant risk factors, such as smoking status.
Taken together, the available studies do not provide an
nswer to the question regarding the clinical significance of
he metabolic syndrome in hypertension. High BP is a
the Single Components of the Metabolic
revalence
(%)
Adjusted HR*
(95% CI) p Value
34 1.75 (1.26–2.42) 0.001
35 1.71 (1.24–2.36) 0.001
19 1.38 (1.00–1.93) 0.05
29 0.96 (0.72–1.27) 0.80
erum total cholesterol concentration, serum creatinine, ande of
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May 19, 2004:1817–22 Prognosis of the Metabolic Syndromeajor (25) and independent (26) cardiovascular risk factor.
n the other hand, hypertension tends to cluster with
etabolic risk factors, and about half of patients with
ssential hypertension are insulin-resistant (10,27). Coro-
ary risk continues to be higher in drug-treated hypertensive
atients than in normotensive individuals (28,29), and some
f this difference might be due to the presence in hyperten-
ive patients of additional metabolic risk factors, which have
een collectively identified as the metabolic syndrome.
The ATP-III guidelines recognize that the metabolic
yndrome enhances the risk of coronary heart disease (4),
nd the prognostic value of the metabolic syndrome for
ncident coronary heart disease (5), cardiovascular disease
6), cardiovascular mortality (7,24), and all-cause mortality
3) has been established in different clinical settings. In the
elsinki Policemen Study (30), risk factor clustering of
nsulin resistance syndrome predicted both coronary heart
isease and stroke. In our study, we found, for the first time,
hat the metabolic syndrome, defined by ATP-III, is an
ndependent predictor of cerebrovascular and cardiac events.
ur finding of an increased risk of two different manifes-
ations of atherosclerotic disease in hypertensive patients
ith the metabolic syndrome is in agreement with the
ypothesis that insulin resistance, per se, might accelerate
he development of atherosclerosis. As a matter of fact, the
etabolic syndrome has been associated with progressive
arotid atherosclerosis (31), as well as to coronary athero-
clerosis (32). On the other hand, individuals with the
etabolic syndrome tend to have systemic endothelial
ysfunction (33) and chronic subclinical inflammation (34),
hich are increasingly recognized as powerful risk factors
or cardiac and cerebrovascular events (35–37).
tudy limitations. The present study has some limitations.
ecause our findings have been obtained in initially un-
reated white subjects, the results may not be extended to
ifferent ethnic groups or to subjects receiving antihyper-
ensive treatment at the time of the qualifying examination.
he PIUMA data base does not include information on BP
able 4. Independent Predictors of Cardiovascular Morbidity
nd All-Cause Mortality in 1,637 Nondiabetic Hypertensive
atients in a Multivariate Cox Model
Variable
Adjusted HR*
(95% CI) p Value
etabolic syndrome (yes vs. no) 1.43 (1.02–2.08) 0.03
ge (12 yrs) 2.10 (1.72–2.55) 0.001
ender (male vs. female) 1.80 (1.18–2.75) 0.007
igarette smoking (yes vs. no) 1.92 (1.31–2.82) 0.001
4-h systolic BP (15 mm Hg) 1.36 (1.16–1.60) 0.001
erum cholesterol (1 mmol/l) 1.20 (1.00–1.45) 0.05
erum creatinine (18 mol/l) 1.11 (1.01–1.23) 0.04
eft ventricular hypertrophy (yes vs. no) 1.96 (1.28–3.00) 0.002
For continuous variables, the adjusted hazard ratio associated with each 1-SD
ncrease is reported. A family history of premature cardiovascular disease, office blood
ressure, heart rate, and treatment status (antihypertensive, hypolipidemic and
spirin) failed to enter the final equation.
Abbreviations as in Table 2.ontrol during follow-up in the whole population; theseata were available in about 30% of the study subjects.
nother limitation inherent to observational cohort studies
s the lack of control for occasional changes in the antihy-
ertensive regimen over time.
erspectives. Our findings suggest that the metabolic syn-
rome represents a strong, independent risk factor for future
ardiovascular disease in hypertensive patients. Over and
bove the prognostic information provided by all other
raditional cardiovascular risk markers (11), the simple,
nexpensive assessment of the metabolic syndrome may
ontribute to further refine cardiovascular risk stratification
n hypertension. Hypertensive patients with the metabolic
yndrome are at increased risk of coronary and cerebrovas-
ular disease and require a more vigorous nondrug and
harmacologic preventive approach. The present finding of
synergistic impact of the metabolic syndrome and hyper-
ension on cardiovascular disease strongly indicates the need
or metabolic screening in all hypertensive patients at the
rst diagnosis.
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